Evidence map›Paper›PMID 33108657›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.

Lino E Torres-Domínguez, Ana Lemos de Matos, Masmudur M Rahman, Grant McFadden

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lino E Torres-DomínguezCenter for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Ana Lemos de MatosCenter for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Masmudur M RahmanCenter for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Grant McFaddenCenter for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ, USA. grantmcf@asu.edu.
Arizona State University · USUniversity of Florida · US

Funding

Studies in Poxvirus Host Range Genes and TropismR01AI080607 · NIAID · UNIVERSITY OF FLORIDA · PI RAHMAN, MASMUDUR MOHAMMED · 2009 to 2025
$5.6M
NIAID NIH HHS R01 AI080607
6 · The paper itself

Abstract

Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.

Indexed as

Genome, ViralAnimalsChlorocebus aethiopsCloning, MolecularGenes, ReporterGenetic EngineeringGreen Fluorescent ProteinsHeLa CellsHumansLuminescent ProteinsMyxoma virusOncolytic VirotherapyOncolytic VirusesPlasmidsRabbitsRecombinant Proteinsenhanced green fluorescent proteinfluorescent protein 583Green Fluorescent ProteinsLuminescent ProteinsRecombinant ProteinsArmed oncolytic virusEngineered virusMyxoma virusOncolytic virotherapyOncolytic virusPoxvirusRecombinant virusViral vector

Identifiers

PMID33108657
PMCPMC8082691
OpenAlexW3097586710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.